BRIEF published on 11/04/2024 at 11:51, 8 months 5 days ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 8 months 5 days ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 8 months 5 days ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 8 months 5 days ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 8 months 29 days ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 8 months 29 days ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 8 months 29 days ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 8 months 29 days ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 1 year ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 1 year ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 07/09/2025 at 20:21, 32 minutes ago Agassi Sports Entertainment utilise les services d’IBM pour améliorer l’expérience des sports de raquette
Published on 07/09/2025 at 20:15, 38 minutes ago Interactive Strength Inc. (Nasdaq: TRNR) Receives "Buy" Rating and $15 Price Target in Maxim Group Research Initiation
Published on 07/09/2025 at 16:00, 4 hours 53 minutes ago Aeonian Receives Drill Permits for Koocanusa Project, Paving the Way for First Pass Testing of Sedimentary Copper Targets
Published on 07/09/2025 at 14:30, 6 hours 23 minutes ago Agassi Sports Entertainment Engages IBM to Help Elevate Racquet Sports Experience
Published on 07/09/2025 at 14:30, 6 hours 23 minutes ago Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement
Published on 07/09/2025 at 18:34, 2 hours 18 minutes ago 2CRSi SA: BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE
Published on 07/09/2025 at 18:33, 2 hours 20 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 07/09/2025 at 17:45, 3 hours 8 minutes ago Charwood Energy: Bilan semestriel du contrat de liquidité contracté avec Kepler Cheuvreux
Published on 07/09/2025 at 17:35, 3 hours 18 minutes ago EQS-Adhoc: Pyrum Innovations AG resolves cash capital increase from authorized capital with exclusion of subscription rights
Published on 07/09/2025 at 18:00, 2 hours 53 minutes ago COGELEC : Legrand and Cogelec Développement's shareholders sign an agreement for Legrand to acquire a majority stake in Cogelec, a French specialist in access control
Published on 07/09/2025 at 18:00, 2 hours 53 minutes ago COGELEC : Legrand et les actionnaires de Cogelec Développement concluent un accord en vue de l’acquisition par Legrand d’une participation majoritaire dans Cogelec, spécialiste français dans le contrôle d’accès
Published on 07/09/2025 at 18:00, 2 hours 53 minutes ago Bilan semestriel du contrat de liquidité au 30 juin 2025
Published on 07/09/2025 at 18:00, 2 hours 53 minutes ago Half-year liquidity contract statement June 30, 2025
Published on 07/09/2025 at 18:00, 2 hours 53 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/06/2025
